Navigation Links
amfAR Announces Funding for HIV Services and Research Aimed at Men Who Have Sex With Men in Developing Countries
Date:2/22/2008

More Than 100 Groups Apply for Grants to Assist Men Who Have Sex With Men in Developing Countries

NEW YORK, Feb. 21 /PRNewswire-USNewswire/ -- In an ambitious move to significantly bolster global HIV program efforts targeting populations especially vulnerable to HIV, amfAR, The Foundation for AIDS Research, has announced the first recipients of funding given out under its new MSM Initiative. These community awards will fund 17 grassroots and frontline organizations in Africa, the Caribbean and Southeast Asia that are working to provide essential HIV/AIDS prevention, care and support services for men who have sex with men (MSM), amfAR CEO Kevin Robert Frost announced today.

"MSM are one of the populations worst affected by HIV worldwide, and this is the first global initiative of its kind supporting local organizations working to address HIV among MSM in developing countries," Frost said.

According to UNAIDS, fewer than one in 20 MSM around the world have access to appropriate HIV/AIDS services. Stigma, discrimination, and lack of access to health services have sparked alarming epidemics that threaten the lives of MSM in underdeveloped regions, mirroring the HIV epidemics that ravaged gay men in North America and Western Europe in the 1980s.

"The MSM Initiative is working to galvanize a much needed global response to the enormous gaps in funding and services for MSM at risk of HIV/AIDS through a partnership with amfAR, UNAIDS, and the Global Forum on MSM and HIV," said Dr. Peter Piot, Executive Director of the Joint United Nations Programme on HIV/AIDS (UNAIDS). "Leadership in the gay community was instrumental in the response to the HIV/AIDS epidemic in the West. This initiative is fostering new leadership and support for this issue in developing countries across the globe, including nations where male-male sex is illegal and often heavily stigmatized."

These awards mark the first funding cycle completed by the MSM Initiative, which was launched just eight months ago in July 2007. First-round funding includes support for organizations working in Cameroon, Côte d'Ivoire, Curacao, Ghana, Haiti, Jamaica, Malaysia, Mali, Mauritius, Myanmar, Nigeria, Thailand and Zimbabwe. The MSM Initiative received more than 120 applications from organizations in developing countries, with more than 85 from Africa alone, far exceeding expectations.

"The response to our first request for proposals (RFP) for funding the MSM Initiative has been overwhelming, demonstrating the enormous unmet need, particularly in parts of the world where vulnerable populations have few established support systems," Frost said. "Through the MSM Initiative, we hope to foster collaboration among organizations, promote advocacy that transforms attitudes and discriminatory policies, and increase HIV/AIDS funding worldwide for MSM."

A second RFP will be issued on February 22. It will target groups working in Central and South America and Asia and the Pacific.

"For too long, countries around the world have simply assumed MSM do not exist, leaving millions underserved and vulnerable to HIV infection," said Stella Iwuagwu, Executive Director at the Center for the Right to Health in Abuja, Nigeria. "The MSM Initiative provides important resources to help us expand our work to empower MSM in Nigeria and ensure that education, condoms, and treatment are available to all."

Data on HIV rates among MSM in developing countries are sparse but a recent study by researchers at Johns Hopkins University produced some startling findings. Published in the online journal PLoS Medicine, their research showed that in 38 low- and middle-income countries, MSM have an average 19 times greater chance of being infected with HIV than the general population. In some countries MSM are more than 100 times more likely to be infected, the study found.

The MSM Initiative is facilitated by amfAR, with valuable support from its partnerships with the Global Forum on MSM and HIV and UNAIDS. Major donors to the MSM Initiative include the Elton John AIDS Foundation, the Elizabeth Taylor AIDS Foundation, GlaxoSmithKline's Positive Action Programme and the M•A•C AIDS Fund.

For more information about amfAR and the MSM Initiative, visit http://www.amfar.org.

ABOUT amfAR

amfAR, The Foundation for AIDS Research, is one of the world's leading nonprofit organizations dedicated to the support of AIDS research, HIV prevention, treatment education, and the advocacy of sound AIDS-related public policy. Since 1985, amfAR has invested $260 million in its programs and has awarded grants to more than 2,000 research teams.


'/>"/>
SOURCE amfAR, The Foundation for AIDS Research
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. ATS Medical Announces Initial Clinical Results of Stand-Alone Atrial Fibrillation Procedures Using ATS CryoMaze Product Line
2. ISTA Pharmaceuticals Announces Physician-Sponsored Clinical Study of Xibrom(TM) Combination Therapy with Lucentis(R)
3. Accumetrics Announces $28.8 Million Financing and Initiation of Pivotal Clinical Trial
4. Bionovo Announces Positive Developments in On-going Phase 1/2 Cancer Drug Trial
5. On Second Anniversary, Compendia Bioscience Announces Significant Revenue Growth, Completion of Product Milestone and Expansion of Pharma Customer Commitments
6. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
7. Advanced Life Sciences Announces Successful Thorough QT Study of Cethromycin
8. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
9. TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds
10. Raven Announces Completion of Enrollment in the Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for the Treatment of Adenocarcinomas
11. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... Sept. 25, 2017  EpiVax, Inc., a leader ... and immune-engineering today announced the launch of EpiVax ... of personalized therapeutic cancer vaccines. EpiVax has provided ... access to enabling technologies to the new precision ... lead EpiVax Oncology as Chief Executive Officer. Gad ...
(Date:9/22/2017)... 22, 2017  As the latest Obamacare repeal effort ... Cassidy (R-LA) and Lindsey Graham (R-SC) ... medical device industry is in an odd place.  The ... 2.3% excise tax on medical device sales passed along ... covered patients, increased visits and hospital customers with the ...
(Date:9/19/2017)... venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that uses pulsed sound ... ... Jim Bertolina, PhD ... Tom Tefft ... device executive Josh Stopek , PhD, who has led R&D and business development teams ...
Breaking Medicine Technology:
(Date:10/13/2017)... , ... October 13, 2017 , ... As health professionals ... known as “patient engagement.” The patient is doing more than filling out a survey; ... , “There is an increasing emphasis in health care and research on the importance ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... ‘17, and Jennifer Huggins, PharmD ’17, along with clinical associate professor Janice ... of cardiovascular diseases during the 15th Annual Women’s Health Conference. The SIU ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Ellevate Network, ... in business to advocate for action towards gender equality at their inaugural Summit in ... around the globe, and reached a social audience of over 3 million. To watch ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to the ... save lost souls in the Philippines. “The Journey: From the Mountains to the Mission ... of the Bible. She has taught all ages and currently teaches a class of ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults ... tested to meet the highest standard. , These products are also: Gluten ...
Breaking Medicine News(10 mins):